Thymosin Beta-4 Anti-Fibrotic Fragment
TB-4 Fragment is a refined segment of the thymosin beta-4 molecule that targets cardiac and vascular fibrosis specifically, blocking the scar-forming process after heart injury while reducing arterial wall stiffness. It delivers the anti-fibrotic benefits of TB-500 with an attenuated angiogenic profile, making it the preferred choice in cardiovascular-focused protocols where stimulating new vessel growth is not desired.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
15 mg
Format
Injectable
Composition
5 mg/ml per ml
The TB-4 Fragment retains the actin-sequestering N-terminal domain of Thymosin Beta-4, inhibiting fibroblast-to-myofibroblast transdifferentiation: the cellular mechanism underlying fibrotic scar formation in cardiac tissue. It modulates TGF-β signalling (a key driver of cardiac fibrosis) and reduces collagen crosslinking enzymes that stiffen cardiac and vascular matrix. Unlike full TB-500, it has attenuated VEGF-mediated angiogenic activity, reducing the risk of stimulating unwanted neovascularisation in contexts where angiogenesis is contraindicated.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
By blocking myofibroblast differentiation, TB-4 Fragment targets the root cause of post-infarction cardiac scarring: preventing the progressive stiffening and dysfunction that follows myocardial damage.
Unlike full TB-500, the fragment's reduced VEGF activation makes it suitable for contexts where systemic angiogenesis is not desired, such as in individuals with borderline vascular conditions or those on specific cancer monitoring protocols.
Reduction of collagen crosslinking in arterial walls supports vascular compliance, potentially relevant in arterial stiffness management and cardiovascular longevity protocols.
Explore selected publications and registered trials on TB-4 Fragment, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Related full-length Thymosin beta-4 preclinical evidence
Publication and key finding
In full-thickness rat wounds, full-length thymosin beta-4 increased re-epithelialization by up to 61%, collagen deposition and angiogenesis.
The Journal of investigative dermatology
Evidence type
Preclinical study
Direct fragment-domain and full-length preclinical evidence
Publication and key finding
Thymosin beta-4 and a synthetic actin-binding-domain fragment accelerated dermal repair in diabetic and aged mice.
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
Evidence type
Review
Related full-length Thymosin beta-4 repair review
Publication and key finding
This review links thymosin beta-4 to cell migration, angiogenesis, reduced inflammation and repair across dermal, corneal and cardiac injury models.
Trends in molecular medicine
Evidence type
Published research
Related full-length Thymosin beta-4 translational review
Publication and key finding
This translational review summarizes thymosin beta-4's roles in cell migration, blood-vessel formation, inflammation control and tissue regeneration.
Expert opinion on biological therapy
Evidence type
Review
Related full-length Thymosin beta-4 mechanism review
Publication and key finding
The review consolidates evidence that thymosin beta-4 supports cytoprotection, angiogenesis and tissue repair through actin regulation.
Annals of the New York Academy of Sciences
5 selected studies from the wider trial library, in the order chosen for this product.
NCT00382174
NCT00832091
NCT01387347
NCT01393132
NCT04555824
Combinations used in research protocols where TB-4 Fragment complements other compounds.
TB-4 Fragment + Cardiogen
The comprehensive cardiac longevity stack: TB-4 Fragment prevents and reverses fibrosis while Cardiogen restores gene expression patterns to youthful cardiac tissue profiles.
View CardiogenTB-4 Fragment + SS-31
Anti-fibrotic plus mitochondrial protection: addresses both the structural scarring and the energy deficit at the core of cardiac ageing and post-ischaemic dysfunction.
View SS-31Follow the product-specific protocol below with qualified professional guidance. For preparation, handling and pen guidance, review the manual.
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
